Liraglutide vs Semaglutide: First-Gen vs Second-Gen GLP-1 Compared
Liraglutide (Saxenda/Victoza) and semaglutide (Wegovy/Ozempic) are both GLP-1 receptor agonists, but semaglutide delivers roughly 2.5x greater weight loss and only requires weekly dosing versus liraglutide's daily injections.
Overview
Liraglutide and semaglutide are both synthetic GLP-1 receptor agonists used to treat type 2 diabetes and obesity, but they represent different generations of the same drug class. Liraglutide (approved 2010) was the first daily-injected GLP-1 to reach broad clinical use, while semaglutide (approved 2017 for diabetes, 2021 for weight) introduced a once-weekly dosing schedule and substantially greater efficacy. Understanding how they differ helps patients and clinicians choose the right therapy.
Quick Comparison
| Feature | Liraglutide | Semaglutide |
|---------|-------------|-------------|
| Brand names | Saxenda, Victoza | Wegovy, Ozempic, Rybelsus |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing frequency | Daily injection | Weekly injection (also oral) |
| Half-life | ~13 hours | ~7 days (165 hours) |
| Max weight loss | 6.4-8.0% | 14.9-15.8% |
| FDA approval year | 2010 | 2017 (diabetes), 2021 (weight) |
| Generic available | Yes (since 2024) | No |
| Oral form | No | Yes (Rybelsus; oral Wegovy 2026) |
| Pediatric obesity | Approved (12+) | Approved (12+) |
| Cardiovascular benefit | Modest (LEADER) | Confirmed (SELECT, 20% MACE reduction) |
Mechanism
Both peptides mimic the endogenous GLP-1 hormone, binding the GLP-1 receptor on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic signaling. The key pharmacokinetic difference is half-life: liraglutide requires daily dosing because albumin binding gives it only a ~13-hour half-life, while semaglutide's modified fatty-acid side chain extends half-life to roughly 7 days, enabling once-weekly injection.
Efficacy (Weight Loss)
The head-to-head STEP 8 trial directly compared high-dose semaglutide (2.4 mg weekly) to liraglutide (3.0 mg daily) over 68 weeks. Semaglutide produced 15.8% mean weight loss versus 6.4% for liraglutide — approximately 2.5x greater. A higher proportion of semaglutide patients (70% vs 25%) achieved at least 15% weight loss. In standalone trials, liraglutide's SCALE program showed 8.0% loss at 3.0 mg, while semaglutide's STEP trials consistently delivered 14.9-15.8%.
Dosing Schedules
- **Liraglutide (Saxenda):** Start 0.6 mg daily, titrate weekly by 0.6 mg to a maintenance dose of 3.0 mg daily. Inject subcutaneously at the same time each day.
- **Semaglutide (Wegovy):** Start 0.25 mg weekly, titrate every 4 weeks through 0.5, 1.0, 1.7, to a maintenance dose of 2.4 mg weekly. Oral Wegovy (absorbed via SNAC enhancer) became available in January 2026 for patients who prefer no injection.
Side Effects
Both share a similar GI-dominated profile: nausea (most common, 30-44% with semaglutide), vomiting, diarrhea, constipation, and abdominal pain. Symptoms typically peak during titration and subside over weeks. Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury. Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent data. Semaglutide shares the same warning. Neither is recommended in pregnancy or with personal/family history of medullary thyroid carcinoma or MEN2.
Cost & Availability
Generic liraglutide (2024) has substantially lowered its price, making it the most affordable GLP-1 option. Semaglutide remains brand-only in the U.S. at a list price near $1,000+ monthly for Wegovy, though manufacturer savings cards and increasing supply have eased access. Oral semaglutide offers a needle-free alternative but at comparable cost.
Which Should You Choose?
**For maximum weight loss:** Semaglutide. Roughly 2.5x greater loss in head-to-head trials.
**For cost-conscious patients:** Generic liraglutide, the only generic GLP-1 agonist.
**For pediatric patients:** Both are approved for obesity in ages 12+, but liraglutide also covers diabetes in ages 10+.
**For oral medication preference:** Semaglutide (Rybelsus or oral Wegovy).
**For cardiovascular risk reduction:** Semaglutide (SELECT trial confirmed 20% MACE reduction; liraglutide's LEADER benefit was smaller).
Both agents are best combined with lifestyle intervention and should be supervised by a clinician who can manage titration and adverse effects.
Related Peptides
Frequently Asked Questions
Is semaglutide stronger than liraglutide for weight loss?
Yes. In the STEP 8 head-to-head trial, semaglutide produced 15.8% weight loss vs 6.4% for liraglutide — roughly 2.5x greater efficacy.
Why does liraglutide need daily dosing while semaglutide is weekly?
Liraglutide's half-life is ~13 hours, while semaglutide's modified structure gives it a ~7-day half-life, allowing once-weekly injection.
Is there a generic GLP-1 agonist available?
Yes, generic liraglutide became available in 2024, making it the most affordable GLP-1 option. Semaglutide is still brand-only.
Do both drugs have the same side effects?
Yes, both share a GI-dominated profile (nausea, vomiting, diarrhea) and carry a boxed warning for thyroid C-cell tumors. Semaglutide's higher doses cause more frequent GI effects during titration.
Can I switch from liraglutide to semaglutide?
Yes, under clinician supervision. Most clinicians overlap or transition during the titration phase to manage tolerance and GI side effects.
References
- Wilding JPH, et al. STEP 1: Once-Weekly Semaglutide in Adults with Obesity. N Engl J Med 2021;384:989-1002.
- Garvey WT, et al. STEP 8: Semaglutide 2.4 mg vs Liraglutide 3.0 mg. JAMA 2023;329:335-346.
- Pi-Sunyer X, et al. SCALE Obesity and Prediabetes (Liraglutide 3.0 mg). N Engl J Med 2015;373:11-22.
- FDA Prescribing Information: Wegovy (semaglutide) and Saxenda (liraglutide).